In the news.
Common questions and answers about TIL therapy for cancer.
The FDA approved the first TIL therapy for cancer on Feb. 16 with the approval of Amtagvi to treat advanced melanoma. Here are common questions and answers about this cancer cell therapy.
Read MoreCommon questions and answers about TIL therapy for cancer.
The FDA approved the first TIL therapy for cancer on Feb. 16 with the approval of Amtagvi to treat advanced melanoma. Here are common questions and answers about this cancer cell therapy.
Read MoreACGT donor shares desire to make ‘real impact’ in cancer research.
Leigh Haskell Perkins III shares how at a young age she became an ACGT donor and supporter of advancing cell and gene therapy research, which she continues today.
Read MoreACGT donor shares desire to make ‘real impact’ in cancer research.
Leigh Haskell Perkins III shares how at a young age she became an ACGT donor and supporter of advancing cell and gene therapy research, which she continues today.
Read MoreFDA approves first cancer cell and gene therapy for solid tumor.
The U.S. Food and Drug Administration approved a type of cell and gene therapy called tumor-infiltrating lymphocyte therapy for the treatment of advanced melanoma. It’s a historic approval, the first cell and gene therapy for a solid tumor.
Read MoreFDA approves first cancer cell and gene therapy for solid tumor.
The U.S. Food and Drug Administration approved a type of cell and gene therapy called tumor-infiltrating lymphocyte therapy for the treatment of advanced melanoma. It’s a historic approval, the first cell and gene therapy for a solid tumor.
Read More